CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Australia’s Labour Market Weakens as November Employment Drops Sharply 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Gold Prices Slip Slightly in Asia as Silver Nears Record Highs on Dovish Fed Outlook 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Asian Currencies Hold Steady as Indian Rupee Slides to Record Low on Fed Outlook 
Asian Stocks Rally as Tech Rebounds, China Lags on Nvidia Competition Concerns 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Japanese beer and beverage maker Kirin is selling its China soft drinks joint venture to a Chinese investment fund, Plateau Consumer, for $994 million to enhance its pharmaceutical business.
The sale covers Kirin’s entire 40 percent stake in China Resources Kirin Beverages.
Established in 2011, China Resources Kirin Beverage had been expanding its business in China, making bottled water and bottled tea.
The move was part of its recent decision to review its investment portfolio, including foreign operations, under a management plan that runs through 2024. It comes shortly after Kirin decided to pull out of a joint venture brewery in Myanmar.
Kirin is focusing on certain areas, including pharmaceuticals and health science as well as food and beverages.
The Tokyo-based company has been streamlining its operations to focus on pharmaceutical projects like developing drugs for diseases that have no existing treatments and working on what it calls LC-Plasma to offer products that help maintain immune systems.
Kirin is among Japan’s top beer brands, and still has various global operations, including Four Roses Distillery in the U.S. and San Miguel Brewery in the Philippines.
.
